Business
HardmanResearch: Affimer Drug Conjugates a reality
HardmanResearch: Affimer Drug Conjugates a reality.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nRNS Number : 8785B Avacta Group PLC 15 January 2018 \n\nHardman Research: Affimer Drug Conjugates a reality\nAffimer Drug Conjugates a reality - Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry. Avacta has made considerable progress towards its strategic goal to be ready to enter first-in-man Affimer trials by the end of 2019. In addition, Avacta is using external collaborations to expand the opportunities for its Affimer technology. A proof-of-concept study combining its Affimer technology with Glythera's Permalink chemistry to generate Affimer Drug Conjugates has concluded successfully.\nPlease click here for the full report:\nhttp://www.hardmanandco.com/docs/default-source/company-docs/avacta-documents/15.01.18-affimer-drug-conjugates-a-reality.pdf\n\n\n\n\nTo contact us:\nHardman & Co\n35 New Broad Street\nLondon\nEC2M 1NH\nFollow us on Twitter @HardmanandCo\n\n\nContacts:\nDr Martin Hall\nDr Dorothea Hill\nDr Gregoire Pave\n \n+44 20 7194 7622\n\n\n \[email protected]\[email protected]\[email protected]\n \nwww.hardmanandco.com\n\n\n\n\nAbout Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\nOur research is provided for the use of the professional investment community, market counterparties and sophisticated and high net...